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Abstract
Background: Current HIV treatment guidelines recommend antiretroviral treatment (ART) initiation for all HIV-infected
individuals regardless of CD4 count. This study evaluates the immunological and virological status and the clinical
characteristics of patients who have started ART in the last 8 years in the Northwest of Spain. Methods: All HIV-infected
patients who have started ART between January 2009 and December 2016 at a reference hospital in the Northwest of Spain were
included in this retrospective observational study. Epidemiological, clinical, and immunovirological features and antiretroviral
drugs used for initiation were recorded. A statistical analysis was performed using SPSS version 19 software. Categorical and
continuous variables were compared by the specific statistical tests, and a logistic regression model was used to identify time
associated with Center for Disease Control and Prevention (CDC) categories change. Results: A high proportion of HIV-
infected patients (66.7%) had initiated ART with CD4 counts <350 cells/mm3 in the last 8 years. From these, most of them (68.3%)
had <350 CD4 counts at first contact with HIV specialist medical team, 12.2% had no indications for ART initiation in the last clinic
visit before ART initiation according to the national guidelines at that moment, 11.0% were lost to follow-up because of lack of
compliance with scheduled visits and 8.5% of patients refused treatment. A logistic regression model showed that a delay of one
month since the first contact with HIV specialist medical team to ART initiation involves a risk of worsening in the CDC clinical
category (odds ratio: 1.02 [95% confidence interval: 1.012-1.029]; P < .001). A trend towards an earlier start of ART was observed
during 2015 and 2016, likely influenced by the last treatment guidelines recommendations. Conclusion: High proportion of HIV-
infected patients (66.7%) had initiated ART with CD4 counts <350 cells/mm3 in the last 8 years. The main reasons for this problem
were analyzed and an important rate of late diagnosis was identified. However, a trend towards an earlier start of ART was
observed during 2015 and 2016, likely influenced by the last treatment guidelines recommendations. These findings highlight the
need to promote and facilitate HIV testing to reduce the late diagnosis as well as counseling on HIV prevention, treatment, and
linkage care.
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Introduction
The Department of Health and Human Services and European
AIDS Clinical Society treatment guidelines for the initiation of
antiretroviral therapy (ART) in HIV-infected patients have
been updated in the last years based on the available evidence
and the improvement in the safety and convenience of the
treatments.1,2 From 2009 to 2014 only those patients with
CD4 counts below 350 or 500 cells/mm3 with different con-
siderations and levels of evidence, and the presence of, or high
risk for, developing various types of (comorbid) conditions
were the objective for treatment initiation. In 2014 and 2015,
the national HIV treatment guidelines recommend treating all
HIV-infected patients regardless of their immunological status,
based on experts’ opinions.3 This recommendation has
achieved a higher level of evidence in last year,4 due to the
last findings from the 2 large randomized controlled trials
START and TEMPRANO, showing the benefits reducing the
morbidity and mortality associated with the HIV infection of an
earlier ART initiation.5,6
This study evaluates the immunological and virological sta-
tus and the clinical characteristics of patients who have started
ART in the last 8 years in the Northwest of Spain. The results
obtained would help to know and understand the current char-
acteristics for treatment initiation in the last years in our HIV
population to establish the best treatment strategies to improve
the clinical follow-up of these patients.
Methods
This is a retrospective observational study including HIV posi-
tive patients older than 18 years who have started ART at the
University Hospital of A Corun˜a, a reference hospital in the
Northwest of Spain, between January 2009 and December 2016.
The HIV-infection status of patients who have started ART in
the last 8 years was retrospectively evaluated. Epidemiological,
clinical, and immunovirological features of HIV-infected
patients and antiretroviral drugs used for ART initiation were
recorded. Patients who only received post-exposure prophylaxis
or who started ART in other centers or under clinical trials were
excluded from the analysis. Late diagnosis was defined as CD4
count <350 cells/mm3 at the time of HIV diagnosis. In addition,
it has been taken into account if patients started ART with CD4
counts <350, 350 to 500, or >500 cells/mm3. The statistical
analysis was performed using the Statistical Packages for the
Social Sciences software (SPSS 19.0). Categorical variables are
presented as number of cases or percentage and were compared
by the w2 test or Fisher exact test, when appropriate. Continuous
variables are expressed as mean (standard deviation) and com-
pared by Student t test, Mann-Whitney, and Kruskal-Wallis test,
when appropriate. A logistic regression model was used to iden-
tify time associated with Center for Disease Control and Preven-
tion (CDC) categories change. A P value of <.05 was considered
statistically significant.
Results
Baseline Characteristics of the Study Population
A total of 492 HIV-infected patients who have started ART in
the study period were recorded (Table 1). The overall mean
nadir CD4 count was 267.1 + 202.8 cells/mm3 (years 2009:
176.9 cells/mm3; 2016: 393.3 cells/mm3; P < .001). At first con-
tact with our HIV Specialist Medical Team (FirstSMT), the mean
CD4 count was 403.8+ 303.7 cells/mm3 and 45.5% of them had
CD4 count <350 cells/mm3. Among the last years, an increase has
been observed in the average of CD4 counts at FirstSMT from
383.1 + 285.9 in 2009 and 2010 to 479.3 + 341.1 in 2015 to
2016, P ¼ .017. Moreover, the rate of patients with CD4 counts
below 350 cells/mm3 at FirstSMT has significantly fallen from
51% during 2009 to 2010 to 36.6% during 2015 to 2016 (P ¼
.021). Of note, the mean age was higher for patients with CD4
counts in the FirstSMT <350 cells/mm3 compared to those rang-
ing from 350 to 500 cells/mm3 or above 500 cells/mm3 (41.2
versus 36.0 versus 37.4, respectively; P < .001). Conversely,
CD4 counts levels below 350 cells/mm3 have not been associated
with gender (male versus female; P ¼ .351). The overall rate of
mortality at the time of completion of the study was 3.7%.
What Do We Already Know about This Topic?
It was estimated that in Europe, almost 30% of HIV-
infected persons remain undiagnosed with an overall inci-
dence of late presentation around 50% of all HIV cases.
Late presentation of HIV infection is associated with
shorter survival and poor response to treatment, higher
frequency of ART toxicity, increased healthcare costs, and
rates of HIV transmission. Consequences can be even
worse if we delay antiretroviral treatment initiation.
How Does Your Research Contribute to the
Field?
This study evaluates the immunological and virological
status and the clinical characteristics of patients who have
started antiretroviral treatment in the last 8 years in the
Northwest of Spain. The results obtained would help to get
a deep knowledge of the characteristics of our HIV popu-
lation to establish the best strategies for HIV diagnosis,
prevention, and treatment.
What Are Your Research’s Implications toward
Theory, Practice, or Policy?
The research’s implications in real clinical practice are
that we now know the main reasons for antiretroviral treat-
ment delay and we will be able to avoid loss of follow-up.
Moreover, we identified an important rate of late diagnosis
that we didn’t know and still need to improve.
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Time Since HIV Diagnosis to ART Initiation
The overall mean time since HIV diagnosis to FirstSMT was
4.5 + 11.2 months and since FirstSMT until ART initiation
(FirstART) 19.4 + 32.3 months. These figures were main-
tained during the study period. Of note, the time between
FirstSMT and FirstART was >180 days in 42.1% of patients.
Analyzing those patients who have delayed the ART initiation
more than 180 days, those who required treatment according to
guidelines in force at the time (54.1%) delayed it due to
patients’ refusal of ART initiation (22.2%), no indication of
treatment in the previous follow-up (17.4%), and lack of com-
pliance with the scheduled visits (14.5%). During the time
between FirstSMT and FirstART, mean RNA-HIV increased
(4.9 + 0.9 versus 5.0 + 0.8 log copies/mL, respectively; P <
.001), and mean CD4 count decreased (403.8+ 303.7 vs 287.2
+ 229.5 cells/mm3, respectively; P < .001). The distribution of
the current CDC staging system varies regarding the year of
FirstART: 57.9% A, 3.5% B, 38.6% C during 2009; and 82.9%
A, 3.9% B, 13.2% C in 2016 (P¼ .002). Of note, 0.8% patients
at CDC clinical category A in FirstSMT moved to category B
and 5.0% to category C at FirstART. None of the patients at
category B in FirstSMT moved to C at FirstART. During the
time elapsed between the first follow-up and the treatment
prescription, there was a worsening in the CDC clinical stage
of 9 patients treated in the first 2 years of the study, whereas
this occurred only in 2 patients among those treated during
2015 and 2016 (P ¼ .041).
A logistic regression model was used to assess the impact of
lapsed time between FirstSMT and FirstART and the risk of
worsening in the CDC clinical category (category A to B or A
to C and category B to C). The results showed that a delay of
one month since the FirstSMT to FirstART involve a risk of
worsening in the CDC clinical stage (odds ratio: 1.02 [95%
confidence interval: 1.012-1.029]; P < .001).
Evolution of Mean CD4 Count at ART Initiation
in the Last 8 Years
Mean CD4 count at FirstART was maintained during the study
period, but a significant increase was observed during 2015 to
2016 (Figure 1): 219.5 + 154.2 (2009-2010) versus 405.8 +
306.8 (2015-2016) cells/mm3 (p < 0.001). Overall, 66.7% of
patients started ART with CD4 counts <350 cells/mm3 (Table
2). From these patients who started treatment with CD4 counts
below 350 cells/mm3, most of them (68.3%) had <350 cells/mm3
at FirstSMT, 12.2% had no indications for ART initiation in
the last clinic visit before ART initiation considering the indi-
cations on national clinical guidelines in each year, 11% were
lost of follow-up because of lack of compliance with the
scheduled visit, and 8.5% of patients refused treatment in one
or more follow-up visits. The rest of the patients (33.3%)
started ART with CD4 counts between 350 and 500 (20.3%) and
>500 cells/mm3 (13.0%). Although in 2009 to 2010 only 6.5% of
patients started ART with CD4 >500 cells/mm3, during 2015 to
2016 this figure increased to 32.6% (P < .001).
Antiretroviral Treatment Combinations
at Treatment Initiation
Regarding the antiretroviral drugs used as FirstART, main
NRTI backbone prescribed was TDF/FTC and combinations
were based on PI in 40.7% of patients and NNRTI in 33.7%
(Table 3). Patients with mean CD4 count at FirstART
<350 cells/mm3 received mainly an PI-based therapy (49.6%), in
patients with CD4 counts ranging from 350 to 500, NNRTI-based
therapies appear to have been predominantly prescribed (51.4%),
and in patients with CD4 >500 cells/mm3 an INSTI-based treatment
(60%;P < .001). During 2015 and 2016, 71.1% of patients initiated
ART with an INSTI-based therapy compared to a less than 8.0% in
the previous years (P < .001).
Discussion
Evidence that all HIV-infected individuals should be treated
regardless of CD4 counts has been provided in different clinical
trials and recommended by different treatment guidelines.1–4
This recommendation aims to prevent further damage to the
immune system, decreasing AIDS-associated morbidity and
mortality, normalizing immune function, and reducing the risk
of transmitting HIV infection to other individuals.1–9 Further-
more, the advancements of ART over the last 20 years, with
easier to take regimens and fewer side effects, should help for
its widespread establishment to all HIV positive patients. How-
ever, decision-making on treatment initiation remains a critical
phase in the care of patients living with HIV and not all HIV-
infected patients are under ART.
This study retrospectively evaluates the characteristics of a
large cohort of HIV positive patients in Northwest of Spain
who have started ART in the last 8 years. They presented a
mean CD4 count of 403.8+ 303.7 cells/mm3 at FirstSMT and
a high rate (45.5%) of late presenters (CD4 count
Table 1. Baseline Characteristics of the Study Population.
Variables N ¼ 492
Demographic-epidemiological
Male (%) 83.7
Age, years (SD) 38.9 (9.9)
Routes of HIV transmission
MSM (%) 50.2
Heterosexual (%) 32.9
IDU (%) 12.8
Unknown (%) 4.1
Race
Caucasian (%) 88.2
Latin (%) 9.6
Black (%) 2.2
Coinfections
Anti-HCV positive (%) 13.4
HBsAg positive (%) 3.7
Abbreviations: HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; IDU,
intravenous drug use; MSM, men who have sex with men.
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<350 cells/mm3). Overall, these data agree to those reported in
our country in recent studies and from European Cohorts.10–14
Reducing late HIV diagnosis and AIDS events are consid-
ered a public health priority. In Spain, HIV testing is generally
performed in case of risk behavior or clinical suspicion, but is
not incorporated as a routine screening. Missed HIV testing
opportunities contribute to the increase in late presenters.11,15
It is essential to promote appropriate strategies to detect HIV
infections earlier and facilitate access to HIV test.
Moreover, 42.1% of patients postponed longer than
6 months treatment initiation and 54.1% of them required ART
according to the national guidelines at that moment. Of them,
half delayed it due to patients’ refusal of ART initiation
(22.2%), even 2 or more times, and the other due to no indica-
tion of treatment in the previous follow-up (17.4%) and lack of
compliance with the scheduled visits (14.5%). In a survey con-
ducted in 9 countries in Europe and Australia to evaluate the
reasons why patients were not under ART, the most common
reasons were a refusal for treatment initiation and the percep-
tion of being asymptomatic and therefore not feel the need to be
treated.16
The study was conducted in a health area providing cover-
age to 547 328 individuals in an extension of 2754 km2. This
scenario might explain in part the lack of compliance with the
scheduled visits, missed or multiple late appointments, because
several patients live in rural zones, far from the high-level
health center, and sometimes with limited resources to reach
the hospital. Other potential barriers to ART access could be
low social connectedness, incarceration, and psychiatric
comorbidities and substance abuse that can complicate
retention-in-care and thus may not benefit from ART.17
It is important to highlight that between FirstSMT and First-
ART, mean CD4 count significantly decreased and 5.0% patients
in CDC clinical category A moves to C category. These figures
are in agreement with others related to a high-income setting.18
Table 3. Antiretroviral Treatment Prescription in Naı¨ve Patients by
Years.
Variables (%)
2009-2010
(n ¼ 99)
2011-2012
(n ¼ 112)
2013-2014
(n ¼ 135)
2015-2016
(n ¼ 146)
Backbone
TDF/FTC 86.9 92.0 82.2 62.8
ABC/3TC 5.1 6.2 17.1 17.9
3TC/AZT 7.1 1.8 0.7 0.0
TAF/FTC 0.0 0.0 0.0 19.3
PI 60.8 42.7 53.6 16.3
NNRTI 37.0 49.4 39.3 12.6
INSTI 2.2 7.9 7.1 71.1
Abbreviations: ABC/3TC, abacavir/lamivudine; INSTI, integrase strand transfer
inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease
inhibitor; TAF/FTC, tenofovir alafenamide fumarate/emtricitabine; TDF/FTC,
tenofovir disoproxil fumarate/emtricitabine; 3TC/AZT, lamivudine/zidovudine.
Table 2. HIV Status of Patients at Antiretroviral Treatment Prescription by Years.
Variables 2009-2010 (n ¼ 99) 2011-2012 (n ¼ 112) 2013-2014 (n ¼ 135) 2015-2016 (n ¼ 146)
Mean CD4, cells/mm3, (SD) 219.5 (154.2) 237.6 (169.4) 249.6 (166.6) 405.8 (306.8)
CD4 count <350 cells/mm3 (%) 78.3 77.5 75.0 45.2
Nadir CD4, cells/mm3, (SD) 205.1 (141.6) 223.4 (152.9) 237.6 (152.4) 371.2 (266.6)
Mean RNA-HIV, log copies/mL, (SD) 5.0 (0.7) 5.2 (0.7) 5.0 (0.8) 4.8 (0.8)
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Figure 1. Evolution of CD4 count levels at antiretroviral treatment (ART) initiation during 2009 to 2016 in the HIV-infected population and late
presenters in each year.
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As national treatment guidelines recommend treating all
HIV-infected patients regardless of CD4 count from 2014 leaves
less opportunity to delay therapy. According to recent studies,
there are different reasons that might explain rejection of ART
initiation. Therefore, in the future, healthcare providers should
try to identify individual barriers, and be more proactive given
information regard the great benefits of ART, weighing up
together with the patient the pros and cons of treatment to make
them feel comfortable about their decision to start ART.
The main limitations of the study were small sample size,
single-center study, and the retrospective observational design
that might introduced uncontrolled bias.
In conclusion, these findings highlight the need to promote
and facilitate HIV testing to reduce late diagnosis, promote
early counseling interventions on HIV prevention, linkage to
care and treatment.
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